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Abstract: The susceptibility to cannabis dependency results from the influence of numerous factors
such as social, genetic, as well as epigenetic factors. Many studies have attempted to discover a
molecular basis for this disease. However, our study aimed at evaluating the connection between
altered methylation of the dopamine transporter gene (DAT1) promoter CpG sites and cannabis
dependency. In the cases of some DNA sequences, including the DAT1 gene region, their methylation
status in blood cells may reflect a systemic modulation in the whole organism. Consequently,
we isolated the DNA from the peripheral blood cells from a group of 201 cannabis-dependent patients
and 285 controls who were healthy volunteers and who were matched for age and sex. The DNA
was subjected to bisulfite conversion and sequencing. Our analysis revealed no statistical differences
in the general methylation status of the DAT1 gene promoter CpG island between the patients and
controls. Yet, the analysis of individual CpG sites where methylation occurred indicated significant
differences. These sites are known to be bound by transcription factors (e.g., SP1, p53, PAX5, or GR),
which, apart from other functions, were shown to play a role in the development of the nervous
system. Therefore, DAT1 gene promoter methylation studies may provide important insight into the
mechanism of cannabis dependency.
Keywords: dopamine transporter gene; DAT1; cannabis; epigenetics; dependency; CpG sites
1. Introduction
Epigenetics refers to the processes that modify the regulation of genes without disrupting the DNA
sequence. These processes may result in distinguishing a phenotype [1–5]. Consequently, genes might
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be turned on or off, which is also associated with exposure to certain agents, such as psychoactive
substances. DNA methylation has been associated with behavioral abnormalities [6,7]. Accordingly,
epigenetic alterations, including methylation status, might reflect environmental conditions and a
person’s lifestyle. Therefore, epigenetic alterations may be used as biological markers that demonstrate
metabolic dysfunctions [4,8,9]. Altogether, epigenetics may become a vital aspect of clinical diagnostics,
as it encompasses the regulation of gene expression mediated by DNA methylation, nucleosome
structure and positioning, posttranslational modifications of nucleosome histones, histone replacement,
and RNA interference [10]. We understand that epigenetic alterations function to repress or activate
genes, but since they are not fully understood, they may have other functions.
One of the most commonly studied and well-known epigenetic mechanisms is DNA methylation.
It involves the addition of a methyl group to position C5 of cytosine at the CpG site [3,7] by DNA
methyltransferase (DNMT) to form 5-methylcytosine (5-mC). 5-mC is an epigenetic marker that allows
the expression of some genes but represses others [11], and may be passed on to the succeeding
generations by means of cell division. Methylation alters chromatin packaging and makes it more
condensed and consequently less available for transcription factors in general.
The regulation of DNA methylation has been analyzed in numerous physiological and behavioral
phenotypes in animal models. Notably, it has been proven to be involved in neuronal and brain
development [12–14]. In human studies, methylation dysregulation has been observed in individuals
with substance dependency, anxiety, depression, autism, schizophrenia, and bipolar disorder [6,14–16].
Substance dependency involves long-term behavioral abnormalities that occur in response
to repeated exposure to psychoactive substances in susceptible individuals. It is a multifactorial
syndrome involving a complex interplay between genes and the environment. The data suggest that the
underlying mechanisms regulating these persistent behavioral abnormalities involve changes in gene
expression throughout the brain’s reward circuitry, particularly in the mesolimbic dopamine system.
In the past decade, investigations have revealed the genes potentially involved in the risk of substance
dependency using genome-wide association studies. These investigations have also established the
crucial role of epigenetic mechanisms in mediating the enduring effects of drug abuse on the brain in
animal models of dependency. Genetic variants have been proven to be involved in the onset and
development of dependence on psychoactive substances. Interactions between environmental and
genetic risk factors have also been proven to contribute to the onset and development of dependency,
as environmental risk factors tend to have a greater effect in children with a genetic vulnerability.
Thus, given the link between genetics and one’s environment, epigenetics may play a crucial role in
dependency pathogenesis [17].
Marijuana, which has high levels of tetrahydrocannabinol (THC), is one of the most popular
psychoactive substances. Globally, over 180,000,000 people use cannabis, and approximately 9% of
them become dependent. When individuals begin using cannabis in adolescence, their dependency on
it increases up to 16%, and reaches 50% if cannabis is used daily [18,19]. The studies on the impact
of THC on epigenetic modifications showed altered histone methylation and acetylation in mouse
immune cells that changed the expression of genes involved in the immune response [20]. The study
of striatal mRNA levels in adolescent and adult mouse offspring with parental THC exposure showed
a downregulation of gene promoters and changes in mRNA expression connected to differentially
methylated region (DMR)-associated genes participating in glutamatergic synaptic regulation within
the nucleus accumbens [21]. The impact of the mother’s and the infant’s exposure to THC during
pregnancy was analyzed in the context of methylation changes in the dopamine receptor 4 DRD4 gene.
The study found no evidence of epigenetic modifications. A higher rate of DNA methylation was
observed when the methylation status of other genes from the dopaminergic system was analyzed
in a group of adult cannabis users in the dopamine receptor 2 (DRD2) and the neural cell adhesion
molecule (NCAM) [22].
As mentioned above, the dopaminergic system plays a central role in the development of substance
dependency. The concentration of extracellular dopamine levels is driven by its transporter encoded by
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the dopamine transporter (DAT1) gene [23]. We are unaware of any studies concerning the methylation
status of the dopamine transporter gene in cannabis-dependent subjects with the exception of studies
regarding that issue in the context of alcohol dependency [24–26], striatal dopamine transporter
availability in ADHD (attention-deficit hyperactivity disorder) [27], gambling [28], and impulsivity [29]
in animal studies.
Due to the crucial role the dopaminergic system plays in all substance use disorders, we looked to
analyze the methylation status of 33 CpG sites located in the dopamine transporter gene promoter
region in a group of cannabis dependent subjects.
Modulation of DNA methylation, both at specific GpC sites or at sites in the genome as a whole,
is supposedly associated with numerous health outcomes. When cancer patients are examined,
most of these changes are found at the tissue level in a tissue-specific manner. However, there
are still some concerns regarding methylation changes in white blood cells (WBCs), as they may
be a useful biomarker for various diseases. Epidemiological studies showed possible associations
between global leucocyte DNA methylation and some cancers or schizophrenia [30,31]. It may be that
those alterations observed in blood cells simply reflect some risk factors, such as demographics (age,
gender, race) or environmental exposures (synthetic or organic air pollutants), and other risk factors
(drugs, physical activity and diet, body size, and cigarette smoke or alcohol consumption). Therefore,
large prospective studies are necessary to evaluate methylation status as a risk factor or as a result of
substance dependency.
2. Materials and Methods
2.1. Samples
The study group consisted of 201 male patients diagnosed with a cannabis dependency according
to the International Classification of Diseases, 10th Revision (ICD-10) (mean age = 27.28, SD = 6.06).
The dependent subjects were recruited from the substance use disorder and dependency unit at the
Residential Inpatient Treatment Center in the province of Lubuskie, Poland, after abstaining from
drugs for a minimum of three months. None of the subjects were receiving pharmacotherapy.
The control group comprised of 285 healthy male volunteers matched for age (mean age = 21.91,
SD = 4.08). The patients and controls were all Caucasians from the same region of Poland. The study
was carried out at the Independent Laboratory of Health Promotion, Pomeranian Medical University
in Szczecin. The protocol of the study was accepted by the Bioethics Committee (KB-0012/106/16) and
informed written consent was provided by all participating individuals. All of the participants were
also examined by a psychiatrist.
2.2. Methylation Status Assessment
DNA was extracted from peripheral blood leukocytes using a DNA isolation kit (A&A
Biotechnology, Gdynia, Poland) as previously described [24] and stored at −20 ◦C. A bisulfite
modification of 250 ng DNA was performed using the EZ DNA Methylation Kit (Zymo Research,
Orange, CA, USA) per the manufacturer’s instructions. A methylation-specific PCR assay was carried
out in a Mastercycler epgradient S (Eppendorf, Hamburg, Germany).
Primer oligonucleotides were obtained from Genomed.pl (Warsaw, Poland). Primer sequences
were designed using MethPrimer version 1.0 software (Chinese Academy of Medical Sciences,
Beijing, China, https://www.urogene.org/cgi-bin/methprimer/methprimer.cgi). The status of DAT1
promoter (ENSG00000142319) was assessed by a PCR using primers specific to a fragment of the gene,
i.e., DATF: 5′-GGTTTTTGTTTTTTTTATTGTTGAG-3′; DATR: 5′-AAATCCCCTAAACCTAATCCC-3′.
To successfully amplify the 447 bp fragment covering 33 CpG sites in the DAT1 gene promoter, the
PCR conditions were as follows: initial denaturation (94 ◦C/5 min), followed by 35 cycles (94 ◦C/61
◦C/72 ◦C, 25 s each step), and a final elongation at 72 ◦C for 5 min. The concentration of magnesium
chloride ions was 2.5 mM. After amplification assay, the PCR products were subjected to previously
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described sequencing [24]. Briefly, samples were both verified by sequencing using the BigDye v3.1 kit
(Applied Biosystems, Darmstadt, Germany) and separated by an ethanol extraction using ABI Prism
3130XL (Applied Biosystems, Darmstadt, Germany) in a 36 cm capillary in a POP7 polymer, using the
reverse primer.
Sequencing chromatograms were analyzed using 4Peaks version 1.8 software (Mek & Tosj,
Amsterdam, the Netherlands, https://nucleobytes.com/4peaks/index.html). The methylation of cytosine
was considered positive when the G/A + G ratio reached at least 20% of the total signal (Figure 1).
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2.3. Assessment of the Ability to Bind Transcription Factors
For the analysis of potential transcription binding sites, the DAT1 promoter region sequence was
loaded as a query for PROMO verion 3.0 software (Universitat Politècnica de Catalunya, Barcelona,
Spain, http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). The analysis
was conducted using only sites and human transcription factors. Notably, when using PROMO, weight
matrices are constructed from the known binding sites extracted from version 8.3 of the TRANSFAC
database (http://genexplain.com/transfac/#section0) to identify potential binding sites in sequences.
The ability of transcription factors to bind individual regions was assessed with a different binding
accuracy, i.e., 100%, 95%, or 85%, which corresponds to the rate of similarity between putative and
consensus sequences for a given transcription factor.
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2.4. Statistical Analysis
The data were analyzed using the chi-squared test, with p < 0.05 considered as statistically
significant (GraphPad Prism version 8.0 for Windows, GraphPad Software, San Diego, CA, USA,
www.graphpad.com). The Bonferroni correction for multiple testing was applied to obtain the
Bonferroni critical value.
3. Results
We evaluated the effect of cannabis dependency on the DAT1 promoter methylation status in
patients’ peripheral blood leucocytes in a side-by-side comparison with healthy individuals. We noticed
that both groups presented a similar general methylation level of the CpG island. After we further
explored the status of individual CpG sites, we observed significant methylation status differences in
positions shown in Table 1. Four of these positions were methylated at a higher level (positions 1, 6,
and 28), while nine showed an inverse trend (positions 3, 5, 13, 19, 22, and 25). Deeper analysis using
the Bonferroni correction for multiple tests showed that the difference in CpG site methylation was
greater, especially in positions 1 and 6.
Table 1. The methylation status of 33 DAT1 CpG sites in cannabis-dependent and control subjects.
CpG Site Studied Group MethylationStatus (%) χ
2(p) OR
95% CI
(−95%, +95%)
Spearman’s
R (p)
1 *
dependent N (201) 62% 11.689
(0.001) 0.528
(0.365, 0.763) −0.155
(0.001)control N (285) 46%
2
dependent N (201) 78% 1.992 (0.158) 0.739 (0.485, 1.125)
−0.064
(0.159)control N (285) 72%
3
dependent N (201) 86% 4.986 (0.026) 1.921 (1.075, 3.431) 0.101 (0.026)control N (285) 92%
4
dependent N (201) 25% 0.003 (0.952) 1.013 (0.669, 1.533) 0.003 (0.952)control N (285) 26%
5
dependent N (201) 26% 5.357 (0.021) 1.597 (1.072, 2.377) 0.105 (0.021)control N (285) 36%
6 *
dependent N (201) 18% 16.044
(0.0001) 0.309
(0.170, 0.562) −0.182
(0.0001)control N (285) 6%
7
dependent N (201) 15% 0.289 (0.591) 0.869 (0.522, 1.448)
−0.024
(0.592)control N (285) 14%
8
dependent N (201) 3% 1.499 (0.221) 1.812 (0.691, 4.754) 0.056 (0.222)control N (285) 5%
9
dependent N (201) 36% 0.217 (0.641) 1.093 (0.751, 1.590) 0.021 (0.642)control N (285) 38%
10
dependent N (201) 37% 0.00001
(0.998) 1.000
(0.689, 1.453) 0.0001 (0.998)
control N (285) 37%
11
dependent N (201) 3% 2.360 (0.124) 1.979 (0.816, 4.802) 0.069 (0.125)control N (285) 7%
12
dependent N (201) 30% 0.105 (0.746) 1.067 (0.721, 1.580) 0.015 (0.746)control N (285) 31%
13
dependent N (201) 2% 8.037 (0.005) 3.769 (1.417, 10.022) 0.128 (0.005)control N (285) 9%
14
dependent N (201) 85% 0.046 (0.832) 0.947 (0.577, 1.556)
−0.010
(0.831)control N (285) 84%
15
dependent N (201) 83% 0.019 (0.891) 0.967 (0.602, 1.554)
−0.006
(0.891)control N (285) 82%
16
dependent N (201) 67% 2.594 (0.107) 0.733 (0.502, 1.070)
−0.073
(0.108)control N (285) 60%
17
dependent N (201) 28% 0.266 (0.606) 1.110 (0.746, 1.651) 0.023 (0.607)control N (285) 31%
18
dependent N (201) 7% 0.002 (0.969) 0.986 (0.495, 1.964)
−0.002
(0.969)control N (285) 7%
19
dependent N (201) 92% 7.920 (0.005) 3.435 (1.386, 8.511) 0.128 (0.005)control N (285) 98%
20
dependent N (201) 45% 2.558 (0.110) 0.741 (0.513, 1.070)
−0.072
(0.110)control N (285) 38%
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Table 1. Cont.
CpG Site Studied Group MethylationStatus (%) χ
2(p) OR
95% CI
(−95%, +95%)
Spearman’s
R (p)
21
dependent N (201) 72% 2.441 (0.118) 0.732 (0.495, 1.083)
−0.071
(0.119)control N (285) 65%
22
dependent N (201) 87% 10.045 (0.002) 2.876 (1.461, 5.659) 0.144 (0.001)control N (285) 95%
23
dependent N (201) 19% 0.080 (0.777) 0.935 (0.587, 1.489)
−0.013
(0.777)control N (285) 18%
24
dependent N (201) 70% 0.284 (0.594) 0.899 (0.609, 1.328)
−0.024
(0.595)control N (285) 67%
25
dependent N (201) 25% 5.761 (0.016) 1.632 (1.092, 2.440) 0.109 (0.016)control N (285) 35%
26
dependent N (201) 37% 2.549 (0.110) 1.350 (0.933, 1.953) 0.072 (0.111)control N (285) 45%
27
dependent N (201) 17% 0.143 (0.705) 1.096 (0.681, 1.764) 0.017 (0.706)control N (285) 18%
28
dependent N (201) 73% 6.067 (0.014) 0.611 (0.412, 0.906)
−0.112
(0.014)control N (285) 62%
29
dependent N (201) 25% 1.888 (0.169) 0.738 (0.479, 1.139)
−0.062
(0.170)control N (285) 20%
30
dependent N (201) 10% 0.074 (0.786) 1.084 (0.605, 1.941) 0.012 (0.786)control N (285) 11%
31
dependent N (201) 5% 0.290 (0.590) 1.234 (0.574, 2.653) 0.024 (0.591)control N (285) 7%
32
dependent N (201) 68% 0.004 (0.951) 1.012 (0.686, 1.492) 0.003 (0.951)control N (285) 68%
33
dependent N (201) 73% 2.599 (0.107) 1.413 (0.927, 2.152) 0.073 (0.107)control N (285) 79%
The chi-squared test χ2(p); (OR) odds ratio; (CI) Confidence Interval; R(p) Spearman correlation (−95%, +95%). To
positions 1 and 6, the Bonferroni correction was applied to get the Bonferroni critical value (p = 0.0015).
Since high methylation of the gene promoter usually has a negative impact on the binding
affinity of transcription factors (TFs) [32], we analyzed the TFs’ ability to bind individual regions with
different similarity rates, i.e., 100%, 95%, or 85%. As demonstrated, all the sites with significantly
different methylation statuses in both groups showed a capacity to bind different TFs that play multiple
functions in cell metabolism (Table 2). Notably, one of the factors that might interact with the target
sequence in a methylation-status-dependent manner was PAX5, as it was recognized for its role in
neural development [33].
Table 2. Potential transcription factors capable of binding analyzed CpG sites. The ability of
transcription factors to bind individual regions was assessed with different similarity rates, i.e., 100% (a),
95% (b), or 85% (c).
Matrix Similarity Rate CpG Position Transcription Factor
(a) 100% 3 PAX5
33 PAX5
(b) 95%
1 GCF
3 PAX5
11 RXR-alpha
19 c-Ets-2
20 c-Ets-2
22 PAX5, p53, Sp1
25 AP-2alphaA
28 NFI/CTF
33 PAX5
Brain Sci. 2020, 10, 400 7 of 11
Table 2. Cont.
Matrix Similarity Rate CpG Position Transcription Factor
(c) 85%
1 GCF, E2F1
3 PAX5, p53
5 AhR
6 GR alpha
11 TFII-I, STAT4, RXR-alpha
13 PAX5, p53
19 GR alpha, c-Ets-2, E2F1, GCF
20 c-Ets-2, E2F1, GCF
22 PAX5, p53, E2F1, Sp1
25 GR alpha, AP-2alphaA, NF-AT2
26 PAX5, p53
28 ENKTF1, EBF, E2F1, NFI/CTF
33 PAX5, p53, E2F1
4. Discussion
The legalization of the use of cannabis for medical and recreational purposes has encouraged
regular usage to become increasingly popular. It is one of the most frequently used psychoactive
substances worldwide [19], and as a result, the number of research studies covering all aspects of the
dependency on the substance, including epigenetic modifications, has grown. In the present study,
we analyzed 33 CpG sites located in the promoter region of the DAT1 gene in cannabis-dependent
subjects and in controls. The results of our analyses showed significant differences between both
groups—methylation changes are not similar across all sites. In comparison with the control group,
some sites in the dependent subjects were hypermethylated, while some were hypomethylated. Further,
the assessment of the ability of transcription factors to bind indicated sites revealed a substantial
number of those regulators of gene expression.
Three of the analyzed sites were found to be possible PAX5 transcription factor binding sites
(positions 3, 22, and 33), and all of them were hypomethylated in the group of dependent subjects.
This is crucial, since PAX5 is a transcription factor associated with numerous processes including the
development of the nervous system [34]. Unfortunately, we did not analyze the expression of the
DAT1 gene in our study group, so we are unable to fully anticipate what role this finding may have
in relation to dopaminergic transmission. Additionally, the transcription’s binding ability revealed
that the CpG island covers a sequence that may be bound by ligand-bound GR (position 6). As we
demonstrated, this was the site that showed a significant difference in methylation status after the
Bonferroni correction. This may be of vital importance since glucocorticoids mediate nervous system
functions in substance dependency [35]. In response to this, we concluded that hindering glucocorticoid
responses could change drug-induced reactions, including the modulation of drug-related learning
and memory. Additionally, we postulated that GR may become a promising target in substance use
disorders and dependency therapy [36,37].
As of yet, no studies regarding the DAT1 methylation status have been performed in the
context of cannabinoid dependency, and it is difficult to say if any direct association may be
revealed. Further studies on animal models with the use of DAT1 knock-out animals or chromatin
immunoprecipitation (ChIP) experiments should be performed to reveal which TF or other proteins
may bind DNA in the DAT1 promoter region. However, since neural development and functionality
is determined throughout one’s lifetime, it could not produce expected results. With this said,
among possible TFs, which may bind the DAT1 promoter in selected sites, SP1 can be found. In general,
SP1 is a type of low specificity transcription factor with a wide spectrum of target sequences.
There is the possibility, however, that the DAT1 methylation status might either predispose or
reflect exposure to substances in dependent individuals. Therefore, we do not know if it is more of
a prognostic or diagnostic marker. However, we do know that, functionally, epigenetic alterations
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affect the expression of genes, as measured by RNA and protein synthesis; this may in turn affect the
cellular structure and function and consequently affect the whole body’s metabolism and behavior.
With regard to drug-taking and -seeking behavior, the preclinical literature demonstrated that changes
in the expression of genes, such as brain-derived neurotrophic factor (BDNF) [38] and OPRM1 (the
µ-opioid receptor gene) [39,40], alter the reinforcement properties of drugs including alcohol, cocaine,
and heroin. Thus, epigenetic changes and resultant changes in gene expression may also contribute to
our mechanistic understanding of substance dependencies.
Peripheral tissues have important limitations with respect to generalizability to other tissues
of interest, such as the brain. However, there is a growing amount of evidence that proves that the
numerous epigenetic changes found in peripheral leukocytes and transformed lymphoblasts also
correspond to alterations in the brain cells [41]. Most importantly, a study performed in the previous
year demonstrated that peripheral DAT1 promoter methylation may be a predictive factor of dopamine
transporter availability in the striatum [27].
Another important factor that should be considered when analyzing the epigenetic effects
of THC exposure is the age of a given exposure. Recent animal studies [42,43] showed that the
hippocampus, the amygdala, and the nucleus accumbens are impacted differently by chronic THC
consumption, depending on age. Histone modifications in particular regions were also affected
differently. The adolescent brain showed changes leading to transcriptional repression, whereas the
effect on adults showed transcriptional activation. In adolescent hippocampus and nucleus accumbens,
the initial repression was followed by a counterbalancing response. The authors suggested that
this may have resulted from the adolescent brain being more vulnerable to the adverse effects of
THC [42]. Similarly, adolescent exposure was shown to alter plasticity genes, which are important in
the development of cognitive deficits. The process was mediated by histone modifications and the
altered prefrontal cortex [43].
Conclusively, we think that DAT1 methylation as well as methylation in general should be
more extensively investigated in the context of substance dependency pathogenesis. Future studies
should involve women and not only men, as in our case, as well as subjects of non-Caucasian origin.
Because genetic and epigenetic markers vary by sex and race, the conclusions that can be drawn from
this study are limited. Similarly, expression studies of DAT1 should be performed to fully evaluate the
impact of epigenetic modifications and other genes, as well as their role in dependency. There have
been some reports showing that blood derived samples reveal a significantly lower expression of
DAT1 in substance-dependent patients than in controls [44], but without significant alterations in
DAT1 methylation [44,45]. However, both studies included opioid-dependent patients, which may
constitute a crucial difference to one’s cannabinoid dependency. Findings for DAT1 in other substance
use disorders suggested broader implications for this subset of psychiatric disorder. This is crucial
given the high rates of comorbidity among psychiatric disorders and the potential for comorbidities as
confounding factors [46,47]. Therefore, it seems that DAT1 gene promoter methylation studies may
provide important insights into the mechanism of the development of substance dependency.
There is currently very little research concerning epigenetic, and specifically, methylation changes
in addiction. To the best of our knowledge, there is no study analyzing the methylation of the few
genes in the same group of subjects that also incorporates a full phenotypic description of addiction
(i.e., substance(s), age of onset, number of relapse, and many others), psychometric testing, and single
nucleotide polymorphism (SNP) data, so the question of replicability is still open.
5. Conclusions
The results of our analyses of 33 CpG sites located in the promoter region of the DAT1 showed
significant differences between both analyzed groups (cannabis dependent and controls)—methylation
changes are not similar across all sites. In comparison with the control group, some sites in the
dependent subjects were hypermethylated, while some were hypomethylated. Further, the assessment
of the ability of transcription factors to bind indicated sites revealed a substantial number of those
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regulators of gene expression. Three of the analyzed sites were found to be possible PAX5 transcription
factor binding sites (positions 3, 22, and 33), and all of them were hypomethylated in the group of
dependent subjects. This is crucial, since PAX5 is a transcription factor associated with numerous
processes including the development of the nervous system. Additionally, the transcription’s binding
ability revealed that the CpG island covers a sequence that may be bound by ligand-bound GR (position
6). As we demonstrated, this was the site that showed a significant difference in methylation status
after the Bonferroni correction. Therefore, we conclude that DAT1 gene promoter methylation studies
may provide important insight into the mechanism of cannabis dependency.
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24. Jasiewicz, A.; Rubiś, B.; Samochowiec, J.; Małecka, I.; Suchanecka, A.; Jabłoński, M.; Grzywacz, A. DAT1
methylation changes in alcohol-dependent individuals vs. controls. J. Psych. Res. 2015, 64, 130–133.
[CrossRef] [PubMed]
25. Hillemacher, T.; Frieling, H.; Hartl, T.; Wilhelm, J.; Kornhuber, J.; Bleich, S. Promoter specific methylation of
the dopamine trans-porter gene is altered in alcohol dependence and associated with craving. J. Psychiatr. Res.
2009, 43, 388–392. [CrossRef]
26. Muench, C.; Wiers, C.E.; Cortes, C.R.; Momenan, R.; Lohoff, F.W. Dopamine Transporter Gene Methylation
is Associated with Nucleus Accumbens Activation During Reward Processing in Healthy but not
Alcohol-Dependent Individuals. Alcohol. Clin. Exp. Res. 2018, 42, 21–31. [CrossRef]
27. Wiers, C.; Lohoff, F.W.; Lee, J.; Muench, C.; Freeman, C.; Zehra, A.; Marenco, S.; Lipska, B.K.; Auluck, P.K.;
Feng, N.; et al. Methylation of the dopamine transporter gene in blood is associated with striatal dopamine
transporter availability in ADHD: A preliminary study. Eur. J. Neurosci. 2018, 48, 1884–1895. [CrossRef]
[PubMed]
28. Zoratto, F.; Romano, E.; Pascale, E.; Pucci, M.; Falconi, A.; Dell’Osso, B.; Maccarrone, M.; Laviola, G.;
D’Addario, C.; Adriani, W. Down-regulation of serotonin and dopamine transporter genes in individual
rats expressing a gambling-prone profile: A possible role for epigenetic mechanisms. Neuroscience 2017, 340,
101–116. [CrossRef]
29. Rajala, A.Z.; Zaitoun, I.; Henriques, J.B.; Converse, A.K.; Murali, D.; Epstein, M.L.; Populin, L.C. Dopamine
teransporter gene susceptibility to methylation is associated with impulsivity in nonhuman primates.
J. Neurophysiol. 2014, 112, 2138–2146. [CrossRef]
30. Terry, M.B.; Delgado-Cruzata, L.; Vin-Raviv, N.; Wu, H.C.; Santella, R.M. DNA methylation in white blood
cells: Association with risk factors in epidemiologic studies. Epigenetics 2011, 6, 828–837. [CrossRef]
31. Li, L.; Zheng, H.; Huang, Y.; Huang, C.; Zhang, S.; Tian, J.; Li, P.; Sood, A.K.; Zhang, W.; Chen, K. DNA
methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.
Carcinogenesis 2017, 38, 797–805. [CrossRef]
32. Zhu, H.; Wang, G.; Qian, J. Transcription factors as readers and effectors of DNA methylation. Nat. Rev. Genet.
2016, 17, 551–565. [CrossRef]
33. Available online: https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=
5079 (accessed on 15 May 2020).
34. Adams, B.; Dörfler, P.; Aguzzi, A.; Kozmik, Z.; Urbánek, P.; Maurer-Fogy, I.; Busslinger, M. Pax-5 encodes
the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis.
Genes Dev. 1992, 6, 1589–1607. [CrossRef]
35. Goldfarb, E.V.; Sinha, R. Drug-induced glucocorticoids and memory for substance use. Trends Neurosci. 2018,
41, 853–868. [CrossRef] [PubMed]
Brain Sci. 2020, 10, 400 11 of 11
36. Deroche-Gamonet, V.; Sillaber, I.; Aouizerate, B.; Izawa, R.; Jaber, M.; Ghozland, S.; Kellendonk, C.;
Le Moal, M.; Spanagel, R.; Schütz, G.; et al. The glucocorticoid receptor as a potential target to reduce cocaine
abuse. J. Neurosci. 2003, 23, 4785–4790. [CrossRef] [PubMed]
37. Madalena, K.M.; Lerch, J.K. The Effect of Glucocorticoid and Glucocorticoid Receptor Interactions on Brain,
Spinal Cord, and Glial Cell Plasticity. Neural Plast. 2017, 2017, 8640970. [CrossRef] [PubMed]
38. Vassoler, F.M.; White, S.L.; Schmidt, H.D.; Sadri-Vakili, G.; Pierce, R.C. Epigenetic inheritance of a cocaine
resistance phenotype. Nat. Neurosci. 2013, 16, 42–47. [CrossRef] [PubMed]
39. Zhang, Y.; Landthaler, M.; Schlussman, S.D.; Yuferov, V.; Ho, A.; Tuschl, T.; Kreek, M.J. Mu opioid receptor
knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the
rewarding and locomotor effects of heroin. Neuroscience 2009, 158, 474–483. [CrossRef] [PubMed]
40. Lasek, A.W.; Janak, P.H.; He, L.; Whistler, J.L.; Heberlein, U. Downregulation of mu opioid receptor by RNA
interference in the ventral tegmental area reduces ethanol consumption in mice. Genes Brain Behav. 2007, 6,
728–735. [CrossRef]
41. Sun, Y.V.; Turner, S.T.; Smith, J.A.; Hammond, P.I.; Lazarus, A.; van de Rostyne, J.L.; Cunningham, J.M.;
Kardia, S.L. Comparison of the DNA methylation profiles of human peripheral blood cells and transformed
B lymphocytes. Hum. Genet. 2010, 127, 651–658. [CrossRef] [PubMed]
42. Prini, P.; Penna, F.; Sciuccati, E.; Alberio, T.; Rubino, T. Chronic ∆8-THC Exposure Differently Affects Histone
Modifications in the Adolescent and Adult Rat Brain. Int. J. Mol. Sci. 2017, 18, 2094. [CrossRef]
43. Prini, P.; Rusconi, F.; Zamberletti, E.; Gabaglio, M.; Penna, F.; Fasano, M.; Battaglioli, E.; Parolaro, D.; Rubino, T.
Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin
modifications in the prefrontal cortex. J. Psychiatry Neurosci. 2017, 42, 170082. [CrossRef] [PubMed]
44. Kordi-Tamandani, D.M.; Tajoddini, S.; Salimi, F. Promoter Methylation and BDNF and DAT1 Gene Expression
Profiles in Patients with Drug Addiction. Pathobiology 2015, 82, 94–99. [CrossRef] [PubMed]
45. Barros, M.; Dempster, E.L.; Illott, N.; Chabrawi, S.; Maior, R.S.; Tomaz, C.; Silva, M.A.; Huston, J.P.; Mill, J.;
Müller, C.P. Decreased methylation of the NK3 receptor coding gene (TACR3) after cocaine-induced place
preference in marmoset monkeys. Addict. Biol. 2013, 18, 452–454. [CrossRef]
46. Lohoff, F.W.; Bloch, P.J.; Hodge, R.; Nall, A.H.; Ferraro, T.N.; Kampman, K.M.; Dackis, C.A.; O’Brien, C.P.;
Pettinati, H.M.; Oslin, D.W. Association analysis between polymorphisms in the dopamine D2 receptor
(DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. Neurosci. Lett. 2010, 473, 87–91.
[CrossRef]
47. Wetherill, R.R.; Jagannathan, K.; Lohoff, F.W.; Ehrman, R.; O’Brien, C.P.; Childress, A.R.; Franklin, T.R. Neural
correlates of attentional bias for smoking cues: Modulation by variance in the dopamine transporter gene.
Addict. Biol. 2014, 19, 294–304. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
